www.gliomark.eu

GLIOMARK GA673737

SME INSTRUMENT PHASE 2

"Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography"

ΕΘΝΙΚΟ ΙΔΡΥΜΑ ΕΡΕΥΝΩΝ, 3 ΝΟΕΜΒΡΙΟΥ 2015

Presented by:

Dr. Alex Strongilos, CEO

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 673737



99mTc-Tetrofosmin complex



Fig. 4: A. TTF/SPECT: recurrent glioma characterized by intense TTF uptake (L/N: 8.7). B: Corresponding MRI



Fig. 5: A. SPECT/TTF: radiation necrosis exhibiting only mildly increased TTF uptake (L/N: 2.9). B: Corresponding MRI



Fig. 6: A. SPECT/TTF: high grade glioma with strongly increased TTF uptake (L/N: 16.0). B: Corresponding MRI image.



Fig. 7: Left: SPECT/TTF: low grade glioma (L/N: 1.8). Right: Corresponding MRI image.

The value of ^{99m}Tc-tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme. George A Alexiou, Spyridon Tsiouris, Athanasios P Kyritsis, George Fotakopoulos, Anna Goussia, Spyridon Voulgaris, Andreas D Fotopoulos Journal of Nuclear Medicine 11/2010; 51(12):1923-6. · 5.77 Impact Factor

pro-Actina

C & T

HORIZON 2020
Excellent Science
Global Challenges
Competitive Industries
Open to the world!

SME INSTRUMENT
The SMEs "Champions League"

IDEA

MARKET

Phase 1	Phase 2	Phase 3
Concept & Feasibility Assessment	R&D, Demonstration, Market Replication	Commercialization

Input: "Business Plan 1" (~ 10 pages)

- Feasibility of concept
- Risk Assessment
- IP regime
- Partner Search
- Design Study

Lump sum: ≈ 50,000 € ≈ 6 months

Input: "Business Plan 2" +description of activities Phase 2 (~ 30 pages)

- Development, prototype, test
- Miniaturization/design
- Clinical trials

1 to 2,5 mn € 12-24 months

Input: Promotion of idea

- Facilitate access to private finance
- Support by means of networking, trainings, knowledge sharing and dissemination

No Funding

Clinical research for the validation of biomarkers and/or diagnostic medical devices (Phase 1)



pro-Actina C & T HORIZON 2020 Excellent Science Global Challenges Competitive Industries Open to the world!

EUROPEAN COMMISSION

H2020 SME
Head of Unit

Brussels,

Alex STRONGILOS
PRO-ACTINA CHIMIKI TECHNOLOGIA ANONIMI ETAIRIA
ARCHIMIDOUS STREET 59
194 00 ATHINA
GREECE

Subject: information about the outcome of the evaluation
H2020 - H2020-SMEINST-1-2014
650532 - BIOPHOS

Based on the evaluation results, we regret to inform you that the Agency has decided that no financial contribution could be made for your proposal. The decision was motivated by the following:

The score obtained by your proposal does not reach the minimum threshold.

We recognise the effort you have put into submitting an application for a H2020 SME Phase 1 funding. If you want to improve your application and are considering re-submitting, we recommend that you contact an adviser from the EEN network (http://een.ec.europa.eu/). We hope that despite the disappointing result, you will find other ways of carrying out the business ideas reflected in your proposal.

Proposal Evaluation Form

EUROPEAN COMMISSION

Horizon 2020 - Research and Innovation Framework Programme

Evaluation Summary Report

Evaluation Summary Report

Evaluation Result

Total score: 7.61 (Threshold: 13.00)

Criterion 1 - Impact

Score: **3.00** (Threshold: 4.00/5.00 , Weight: 100.00%)
Good. The proposal addresses the criterion well, although improvements would be necessary.

Criterion 2 - Excellence

Score: **2.66** (Threshold: 4.00/5.00 , Weight: 100.00%)
Fair to good. While the proposal broadly addresses the criterion, there are some weaknesses.

Criterion 3 - Quality and efficiency of implementation

Score: **1.95** (Threshold: 4.00/5.00 , Weight: 100.00%)
Poor. The criterion is addressed in an inadequate manner, or there are serious inherent weaknesses.

Clinical research for the validation of biomarkers and/or diagnostic medical devices (Phase 2)

European Commission - Research - Participants
Proposal Submission Forms

Horizon 2020

Call: H2020-SMEINST-2-2014

Topic: PHC-12-2014

Type of action: SME-2

Proposal number: SEP-210225391

Proposal acronym: GLIOMARK

EUROPEAN COMMISSION

Executive Agency for Small and Medium-sized Enterprises (EASME)

Unit A2

Head of Unit

Brussels,

Alex STRON
PRO-ACTIN
ANONIMI ET
ARCHIMIDOU
194 00 ATHINA
GREECE

Subject: Result of Evaluation of proposals / Invitation to grant prepar
Programme/Call: H2020 — H2020-SMEINST-2-2014
Proposal: 673737 — GLIOMARK

Dear **Alex STRONGILOS**,

We are pleased to inform you that the aforementioned proposal has been **favourably evaluated** by the Agency. Consequently, we wish to proceed to the preparation of the Grant Agreement based on your proposal.

Proposal Evaluation Form

EUROPEAN COMMISSION

Horizon 2020 - Research and Innovation Framework Programme

Evaluation Summary Report

Call:	H2020-SMEINST-2-2014_17-12-2014
Funding scheme:	SME instrument phase 2
Proposal number:	673737
Proposal acronym:	GLIOMARK
Duration (months):	48
Proposal title:	Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography
Activity:	PHC-12-2014

Evaluation Summary Report

Evaluation Result

Total score: 13.02 (Threshold: 12.00)

Criterion 1 - Impact

Score: **4.36** (Threshold: 4.00/5.00 , Weight: 100.00%)

Criterion 2 - Excellence

Score: **4.44** (Threshold: 3.00/5.00 , Weight: 100.00%)

Criterion 3 - Quality and efficiency of implementation

Score: **4.22** (Threshold: 3.00/5.00 , Weight: 100.00%)

Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the s

Keys to success:

1. **Excellent & Innovative idea**
2. **Selection of partners**
3. **Solid Strategy**
4. **Impact**
   - **Company**
   - **Country**
   - **European Union (patients, health**
5. **Implementation**
6. **Commercialization plan / Competition**
7. **Securing Intellectual property / Freedom to operate**
8. **Dissemination of knowledge**

EU's Main Evaluation Criteria:

- ***Excellence in Innovation***
- ***Economic & social impact***
- ***Implementation***


WP9 Management & administration
WP2 Prep phase II
WP1 Regulatory
WP3 Conduct phase II
WP4 Analyse phase II
WP5 Prep phase III
WP6 Conduct phase III
WP7 Analyse & publish phase II
WP 8 GMP Manufacturing
WP10 Exploitation & communication

pro-Actina

C & T

HORIZON 2020
Excellent Science
Global Challenges
Competitive Industries
Open to the world!

Congratulations, you are among the 6% of successful proposals under the European Commission's SME Instrument funding programme. Your project is highly important to

HORIZON 2020

GLIOMARK

Project reference: 673737
Funded under: H2020-EU.2.3.1., H2020-EU.3.1.

Validation of blood-brain-barrier permea
the radiotracer 99mTc-tetrofosmin and
tomography

From 2015-07-01 **to** 2019-07-01, ongoing project

Project details

Total cost:	**Topic(s):**
EUR 4 705 344	PHC-12-2014 - Clini
EU contribution:	diagnostic medical
EUR 4 705 344	**Call for propos**
Coordinated in:	H2020-SMEINST-2-1
Germany	**Funding scheme**
	SME-2 - SME instru

WWW.GLIOMARK.EU

www.gliomark.eu

pro-Actina

C & T

HORIZON 2020
Excellent Science
Global Challenges
Competitive Industries
Open to the world!

Horizon 2020 SME Instrument beneficiaries

Last update: 07/09/2015

Phase 1 | Phase 2

EASME
Executive Agency for Small and Medium-sized Enterprises

https://ec.europa.eu/easme/en/sme-instrument-beneficiaries

pro-Actina

C & T

HORIZON 2020
Excellent Science
Global Challenges
Competitive Industries
Open to the world!

Horizon 2020 SME Instrument beneficiaries

Last update: 07/09/2015

Phase 1 | Phase 2

EASME
Executive Agency for Small and Medium-sized Enterprises



https://ec.europa.eu/easme/en/sme-instrument-beneficiaries

www.gliomark.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 673737